PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8115274-1 1994 A 20-month-old girl with massive digitoxin intoxication (initial digitoxin serum level: 629 ng/ml) was successfully treated with digoxin-specific antibody fragments (Fab). Digitoxin 33-42 FA complementation group B Homo sapiens 166-169 8115274-1 1994 A 20-month-old girl with massive digitoxin intoxication (initial digitoxin serum level: 629 ng/ml) was successfully treated with digoxin-specific antibody fragments (Fab). Digitoxin 65-74 FA complementation group B Homo sapiens 166-169 8115274-3 1994 Free serum-digitoxin disappeared after 6 vials of Fab (480 mg), but was measurable again on days 6 and 7. Digitoxin 11-20 FA complementation group B Homo sapiens 50-53 1469187-0 1992 Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies. Digitoxin 35-44 FA complementation group B Homo sapiens 61-64 1469187-1 1992 A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB). Digitoxin 10-19 FA complementation group B Homo sapiens 130-133 1469187-1 1992 A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB). Digitoxin 10-19 FA complementation group B Homo sapiens 174-177 1469187-1 1992 A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB). Digitoxin 21-25 FA complementation group B Homo sapiens 130-133 1469187-1 1992 A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB). Digitoxin 21-25 FA complementation group B Homo sapiens 174-177 1469187-7 1992 Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted. Digitoxin 54-58 FA complementation group B Homo sapiens 21-24 2799159-10 1989 We confirm the effectiveness of digoxin-specific Fab antibody fragments in life-threatening digitoxin intoxication. Digitoxin 92-101 FA complementation group B Homo sapiens 49-52 6333127-0 1984 Treatment of severe digitoxin intoxication by digoxin-specific Fab antibody fragments. Digitoxin 20-29 FA complementation group B Homo sapiens 63-66 368816-7 1979 So far, due to potential immune reactions, the clinical use of purified digoxin-specific antibodies of Fab fragments is restricted to life-threatening accidental or suicidal digoxin or digitoxin poisoning. Digitoxin 185-194 FA complementation group B Homo sapiens 103-106 15554746-2 2004 Anti-digoxin Fab fragments have been used successfully for many years in the management of severe poisoning with digoxin, digitoxin, and a range of other structurally related compounds, including cardiotoxins from Nerium and Thevetia sp. Digitoxin 122-131 FA complementation group B Homo sapiens 13-16 10217348-0 1999 Effect of digoxin fab antibody on the measurement of total and free digitoxin by fluorescence polarization and a new chemiluminescent immunoassay. Digitoxin 68-77 FA complementation group B Homo sapiens 18-21 8321833-7 1993 RIA was applied to the pharmacokinetic study of sheep digoxin-specific Fab fragments in one patient acutely intoxicated by digitoxin and treated with Digidot. Digitoxin 123-132 FA complementation group B Homo sapiens 71-74 1469187-9 1992 At this time most of the DGTX in serum was FAB-bound. Digitoxin 25-29 FA complementation group B Homo sapiens 43-46 1469187-12 1992 During FAB-treatment total DGTX serum concentrations and renal DGTX clearance rose, indicating redistribution of drug from tissue to serum and urinary elimination of FAB-bound DGTX, respectively. Digitoxin 27-31 FA complementation group B Homo sapiens 7-10 1469187-12 1992 During FAB-treatment total DGTX serum concentrations and renal DGTX clearance rose, indicating redistribution of drug from tissue to serum and urinary elimination of FAB-bound DGTX, respectively. Digitoxin 63-67 FA complementation group B Homo sapiens 7-10 1469187-12 1992 During FAB-treatment total DGTX serum concentrations and renal DGTX clearance rose, indicating redistribution of drug from tissue to serum and urinary elimination of FAB-bound DGTX, respectively. Digitoxin 63-67 FA complementation group B Homo sapiens 7-10 1997019-12 1991 Fab antibodies have been successfully used to reverse the effects of digoxin, digitoxin, and oleander poisoning. Digitoxin 78-87 FA complementation group B Homo sapiens 0-3 6651078-1 1983 We report a case of severe digitoxin poisoning treated at the stage of ventricular fibrillation by infusion of FAB antidigoxin fragments with low in vitro covering properties. Digitoxin 27-36 FA complementation group B Homo sapiens 111-114 7162976-0 1982 [Digitoxin poisoning: reversing ventricular fibrillation with Fab fragments of anti-digoxin antibody]. Digitoxin 1-10 FA complementation group B Homo sapiens 62-65 7162976-1 1982 Purified Fab fragments of ovine anti-digoxin antibodies (Wellcome Foundation) were used to treat a patient who attempted suicide by absorbing 10 mg of digitoxin (serum concentration 265 micrograms/l). Digitoxin 151-160 FA complementation group B Homo sapiens 9-12 6752715-1 1982 Purified Fab fragments of digoxin-specific antibodies obtained from sheep were used to treat 26 patients with advanced, life-threatening digoxin (23 cases) or digitoxin (3 cases) toxicity. Digitoxin 159-168 FA complementation group B Homo sapiens 9-12 6779736-0 1980 [Treatment of massive digitalis poisoning (20 mg of digitoxin) with anti-digoxin antibody fragments (Fab)]. Digitoxin 52-61 FA complementation group B Homo sapiens 101-104